Andrulis Pharmaceuticals Corp has accused Celgene Corp of infringing and inducing the infringement of one of its patents related to a method of treating cancer.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
11 February 2021 Celgene has filed a lawsuit against Indian drugs manufacturer Dr Reddy’s Laboratories to halt its plan to produce and market generic versions of Pomalyst—Celgene’s multiple myeloma treatment.
11 February 2021 Celgene has filed a lawsuit against Indian drugs manufacturer Dr Reddy’s Laboratories to halt its plan to produce and market generic versions of Pomalyst—Celgene’s multiple myeloma treatment.
11 February 2021 Celgene has filed a lawsuit against Indian drugs manufacturer Dr Reddy’s Laboratories to halt its plan to produce and market generic versions of Pomalyst—Celgene’s multiple myeloma treatment.